BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 19470463)

  • 1. Simultaneous inactivation of Par-4 and PTEN in vivo leads to synergistic NF-kappaB activation and invasive prostate carcinoma.
    Fernandez-Marcos PJ; Abu-Baker S; Joshi J; Galvez A; Castilla EA; Cañamero M; Collado M; Saez C; Moreno-Bueno G; Palacios J; Leitges M; Serrano M; Moscat J; Diaz-Meco MT
    Proc Natl Acad Sci U S A; 2009 Aug; 106(31):12962-7. PubMed ID: 19470463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of ATF3 promotes Akt activation and prostate cancer development in a Pten knockout mouse model.
    Wang Z; Xu D; Ding HF; Kim J; Zhang J; Hai T; Yan C
    Oncogene; 2015 Sep; 34(38):4975-84. PubMed ID: 25531328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Par-4/PTEN connection in tumor suppression.
    Diaz-Meco MT; Abu-Baker S
    Cell Cycle; 2009 Aug; 8(16):2518-22. PubMed ID: 19625770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PTEN deficiency is fully penetrant for prostate adenocarcinoma in C57BL/6 mice via mTOR-dependent growth.
    Blando J; Portis M; Benavides F; Alexander A; Mills G; Dave B; Conti CJ; Kim J; Walker CL
    Am J Pathol; 2009 May; 174(5):1869-79. PubMed ID: 19395652
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PTEN loss-mediated Akt activation increases the properties of cancer stem-like cell populations in prostate cancer.
    Kim RJ; Bae E; Hong YK; Hong JY; Kim NK; Ahn HJ; Oh JJ; Park DS
    Oncology; 2014; 87(5):270-9. PubMed ID: 25139413
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphatase and Tensin Homolog (PTEN) Represses Colon Cancer Progression through Inhibiting Paxillin Transcription via PI3K/AKT/NF-κB Pathway.
    Zhang LL; Mu GG; Ding QS; Li YX; Shi YB; Dai JF; Yu HG
    J Biol Chem; 2015 Jun; 290(24):15018-29. PubMed ID: 25873394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cooperation between FGF8b overexpression and PTEN deficiency in prostate tumorigenesis.
    Zhong C; Saribekyan G; Liao CP; Cohen MB; Roy-Burman P
    Cancer Res; 2006 Feb; 66(4):2188-94. PubMed ID: 16489020
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer.
    Guigon CJ; Zhao L; Willingham MC; Cheng SY
    Oncogene; 2009 Jan; 28(4):509-17. PubMed ID: 18997818
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-regulation of the tumor suppressor PTEN by the tumor necrosis factor-alpha/nuclear factor-kappaB (NF-kappaB)-inducing kinase/NF-kappaB pathway is linked to a default IkappaB-alpha autoregulatory loop.
    Kim S; Domon-Dell C; Kang J; Chung DH; Freund JN; Evers BM
    J Biol Chem; 2004 Feb; 279(6):4285-91. PubMed ID: 14623898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Concomitant loss of EAF2/U19 and Pten synergistically promotes prostate carcinogenesis in the mouse model.
    Ai J; Pascal LE; O'Malley KJ; Dar JA; Isharwal S; Qiao Z; Ren B; Rigatti LH; Dhir R; Xiao W; Nelson JB; Wang Z
    Oncogene; 2014 May; 33(18):2286-94. PubMed ID: 23708662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nuclear factor-κB-dependent microRNA-130a upregulation promotes cervical cancer cell growth by targeting phosphatase and tensin homolog.
    Feng Y; Zhou S; Li G; Hu C; Zou W; Zhang H; Sun L
    Arch Biochem Biophys; 2016 May; 598():57-65. PubMed ID: 27040383
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Loss of Nkx3.1 leads to the activation of discrete downstream target genes during prostate tumorigenesis.
    Song H; Zhang B; Watson MA; Humphrey PA; Lim H; Milbrandt J
    Oncogene; 2009 Sep; 28(37):3307-19. PubMed ID: 19597465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Desmethylanhydroicaritin inhibits NF-kappaB-regulated inflammatory gene expression by modulating the redox-sensitive PI3K/PTEN/Akt pathway.
    Kim JH; Lee G; Cho YL; Kim CK; Han S; Lee H; Choi JS; Choe J; Won MH; Kwon YG; Ha KS; Kim YM
    Eur J Pharmacol; 2009 Jan; 602(2-3):422-31. PubMed ID: 19027002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Par-4 drives trafficking and activation of Fas and Fasl to induce prostate cancer cell apoptosis and tumor regression.
    Chakraborty M; Qiu SG; Vasudevan KM; Rangnekar VM
    Cancer Res; 2001 Oct; 61(19):7255-63. PubMed ID: 11585763
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depletion of SAG/RBX2 E3 ubiquitin ligase suppresses prostate tumorigenesis via inactivation of the PI3K/AKT/mTOR axis.
    Tan M; Xu J; Siddiqui J; Feng F; Sun Y
    Mol Cancer; 2016 Dec; 15(1):81. PubMed ID: 27955654
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enforced C-Src Activation Causes Compartmental Dysregulation of PI3K and PTEN Molecules in Lipid Rafts of Tongue Squamous Carcinoma Cells by Attenuating Rac1-Akt-GLUT-1-Mediated Sphingolipid Synthesis.
    Wu CW; Wang SG; Lee CH; Chan WL; Lin ML; Chen SS
    Int J Mol Sci; 2020 Aug; 21(16):. PubMed ID: 32823607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pten null prostate tumorigenesis and AKT activation are blocked by targeted knockout of ER chaperone GRP78/BiP in prostate epithelium.
    Fu Y; Wey S; Wang M; Ye R; Liao CP; Roy-Burman P; Lee AS
    Proc Natl Acad Sci U S A; 2008 Dec; 105(49):19444-9. PubMed ID: 19033462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The radiosensitization effect of parthenolide in prostate cancer cells is mediated by nuclear factor-kappaB inhibition and enhanced by the presence of PTEN.
    Sun Y; St Clair DK; Fang F; Warren GW; Rangnekar VM; Crooks PA; St Clair WH
    Mol Cancer Ther; 2007 Sep; 6(9):2477-86. PubMed ID: 17876045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PTEN, more than the AKT pathway.
    Blanco-Aparicio C; Renner O; Leal JF; Carnero A
    Carcinogenesis; 2007 Jul; 28(7):1379-86. PubMed ID: 17341655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Murine cell lines derived from Pten null prostate cancer show the critical role of PTEN in hormone refractory prostate cancer development.
    Jiao J; Wang S; Qiao R; Vivanco I; Watson PA; Sawyers CL; Wu H
    Cancer Res; 2007 Jul; 67(13):6083-91. PubMed ID: 17616663
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.